Table 2.

SU14813 is efficacious in s.c. tumor xenograft models

Cell lineInitial tumor volume (mm3)Dose (mg/kg)Percent inhibition, % (days dosing)Percent regression, % (days dosing)P
MV4;11 (human AML, FLT3-ITD)35010 BID64 (18)<0.001
20 BID68 (25)<0.001
40 BID89 (32)<0.001
786-O (human renal, VHL mut)30020 BID35 (9)0.02
40 BID50.5 (9)<0.001
80 QD46.5 (9)<0.001
C6 (rat gliomas, PDGFR-β)30040 BID67 (14)<0.001
80 BID70 (14)<0.001
C6 (rat glioma)10020 BID57 (17)<0.001
40 BID64 (17)<0.001
C6 (rat glioma)15010 BID13 (16)0.4
20 QD21 (16)0.08
20 BID29 (16)0.015
40 QD26 (16)0.05
40 BID50 (16)<0.001
80 QD50 (16)<0.001
Colo205 (human colon, EGFR)30040 BID43 (10)0.008
80 BID54 (10)0.001
MV522 (human colon)150–2003 BID20 (15)0.30
10 BID23 (15)0.24
20 BID30 (15)0.12
40 BID71 (15)<0.0001
80 BID80 (15)<0.0001
  • NOTE: Percentage growth inhibition compared with vehicle-treated control groups is indicated in all cases, except where tumor regression was seen. In this case, maximum percentage regression relative to starting size is indicated. Statistical analyses were done using the two-tailed Student's t test. n = 10 to 20 animals for vehicle groups, n = 8 to 10 animals for treatment groups.